 Daily Mail |
The great cancer betrayal: Number of treatments on approved list for patients …
Daily Mail The blood cancer drug, Rituximab, was the fourth most frequently requested treatment through the Fund last year. Andrew Wilson, chief executive of the Rarer Cancers Foundation, said: ‘This appears to be a clear step backwards for cancer patients in … |
|
Findings on ‘Broadly Neutralizing Antibodies‘ May Be Key to HIV Vaccine
AIDSmeds.com HIV/AIDS Treatment News For the first time, scientists have mapped the coevolution of HIV and the corresponding immune response in a single person, providing vital clues that may help in the development of a vaccine, The New York Times reports. Publishing their findings in … |
|
TIME, TIME Warner ethical questions raised in cancer coverage
HealthNewsReview.org $13,702 for rituximab injection – “a cancer wonder drug called Rituxan…MD Anderson probably gets a volume discount that would make its cost $3,000 to $3,500.” “The president of MD Anderson is paid like someone running a prosperous business. Ronald … |
|
UofL researchers demonstrate that humans develop antibodies to tobacco …
KyForward.com Researchers from the University of Louisville’s Departments of Neurology and Physiology, published their findings in PLOS One demonstrating that men who smoke have antibodies to the tobacco mosaic virus (TMV). These antibodies may interact with a … |
|
Antibodies ‘map’ to vaccine for AIDS found
The Japan Times For the first time, scientists were able to follow the full chain of events leading to the patient naturally producing broadly neutralizing antibodies (BnAbs) — so called because they attack different strains of the human immunodeficiency virus (HIV … |
|
Scientists Uncover Antibodies That Could Lead to AIDS Vaccine
Counsel & Heal After analyzing the H.I.V positive African man from shortly after he was infected until about two years later, scientists discovered that he started to produce “broadly neutralizing antibodies,” which were able to battle about 55 percent of all H.I.V … |
 Hannover Zeitung |
Multiple Sklerose: Daclizumab HYP halbiert Schubfrequenz
Deutsches Ärzteblatt Bochum – Der monoklonale Antikörper Daclizumab HYP, eine Variante des 1999 zur Prophylaxe akuter Abstoßungsreaktionen nach Nierentransplantation eingeführten Immunsuppressivums Daclizumab, hat in einer Phase-II-Studie vielversprechende … Multiple Sklerose: Daclizumab HYP halbiert die Wahrscheinlichkeit von SchübenInformationsdienst Wissenschaft (Pressemitteilung) Vielversprechender neuer Wirkstoff gegen Multiple SklerosederStandard.at |
|
Lancet Publishes SELECT Study of Biogen’s Daclizumab HYP, Biogen Says …
Benzinga Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy … Market opening: Biogen Idec up after positive MS drug studyMarketWatch (blog) |
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of …Financial PostToday Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article…
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of …MarketWatch (press release)Today Biogen Idec (NASDAQ:BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an on…